ライフサイエンスコーパス: ischaemic

1 ts are small lesions that are presumed to be ischaemic.

2 is known to facilitate LTP and contribute to ischaemic acidotoxicity.

3 Ischaemic acute kidney injury (AKI), an inflammatory dis

4 through fructokinase in the pathogenesis of ischaemic acute kidney injury (iAKI).

5 NAM treatment reverses established ischaemic AKI and also prevented AKI in an unrelated tox

6 utic intervention to mitigate progression of ischaemic AKI to CKD in humans.

7 cerbated in this region by two forms of post-ischaemic AMPA receptor (AMPAR) plasticity - namely, ano

8 g that ASIC1a activation contributes to post-ischaemic AMPAR plasticity, our results identify a funct

9 to optimise an individual patient's risk of ischaemic and bleeding events and show that the therapeu

10 es the responses of the brain endothelium to ischaemic and inflammatory injury.

11 oliferation and tissue regeneration in their ischaemic and non-ischaemic limbs.

12 transient increases in liver enzymes, focal ischaemic areas and a robust neutrophil infiltration int

13 emic attack within 1 week of index transient ischaemic attack (dual transient ischaemic attack) after

14 io [OR] 3.8, 95% CI 2.1-7.0), dual transient ischaemic attack (OR 3.3, 95% CI 1.8-5.8), and ipsilater

15 ated with 7 day stroke after index transient ischaemic attack (p<0.001 for all).

16 y for haemorrhagic and ischaemic), transient ischaemic attack (TIA) and subarachnoid haemorrhage (SAH

17 ded for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis

18 with a recent ischaemic stroke or transient ischaemic attack (TIA) were randomised to pioglitazone (

19 ticipants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h of onset.

20 Patients with first-ever stroke/transient ischaemic attack (TIA), >/=18 y, with diagnosis between

21 dothelial cells after experimental transient ischaemic attack and allowed discriminating transient is

22 nd MRI done within 7 days of index transient ischaemic attack and before stroke recurrence.

23 s, in emergency departments, or in transient ischaemic attack clinics.

24 ent data from 16 cohort studies of transient ischaemic attack done in Asia, Europe, and the USA, with

25 ute ischaemic stroke, or high-risk transient ischaemic attack from 674 hospitals in 33 countries.

26 attack and allowed discriminating transient ischaemic attack from epilepsy and migraine, two importa

27 highest risk of early stroke after transient ischaemic attack has been improved with imaging based sc

28 Failure to diagnose transient ischaemic attack is a wasted opportunity to prevent recu

29 During a transient ischaemic attack it is assumed that the affected tissue

30 Transient ischaemic attack management guided by ABCD3-I with immed

31 ilepsy and migraine, two important transient ischaemic attack mimics.

32 that characterize this rodent true transient ischaemic attack model.

33 of patients in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and

34 nts with acute ischaemic stroke or transient ischaemic attack when associated with ipsilateral athero

35 at highest risk of a stroke after transient ischaemic attack with improved risk prediction compared

36 eighted MRI, carotid stenosis, and transient ischaemic attack within 1 week of index transient ischae

37 x transient ischaemic attack (dual transient ischaemic attack) after adjusting for ABCD2 score.

38 ractures, respiratory failure, and transient ischaemic attack) and four events in three patients (2%)

39 charges, head tremor, limb-shaking transient ischaemic attack), bobble-head doll syndrome, spasmus nu

40 (one minor bleeding event and one transient ischaemic attack).

41 a were stroke-specialist confirmed transient ischaemic attack, age of 18 years or older, and MRI done

42 ted that this may also be true for transient ischaemic attack, and that it would be clinically releva

43 ort study in patients with a first transient ischaemic attack, ischaemic stroke, or myocardial infarc

44 ischaemic stroke have a preceding transient ischaemic attack, which is clinically defined as focal n

45 ts, a strain representative of the transient ischaemic attack-prone population.

46 s in a rodent model mimicking true transient ischaemic attack.

47 roke risk scores in patients after transient ischaemic attack.

48 ctin might aid in the diagnosis of transient ischaemic attack.

49 ectin as a potential biomarker for transient ischaemic attack.

50 mmended tissue-based definition of transient ischaemic attack.

51 ambulance in subjects suspected of transient ischaemic attack/early stroke.

52 associated with increased rates of transient ischaemic attacks (TIAs; 4.18 TIAs per 100 person-years

53 'True' transient ischaemic attacks are characterized not only clinically,

54 strokes were identified, but three transient ischaemic attacks occurred in each group.

55 ncluding myocardial infarction and transient ischaemic attacks, assessed in all eligible patients who

56 airment occurring in patients with transient ischaemic attacks.

57 reduce brain damage occurring with transient ischaemic attacks.

58 d neurological signs that resemble transient ischaemic attacks.

59 orm treatment decisions that need to balance ischaemic benefit and bleeding risk in patients with acu

60 nteraction=0.007), and exerted a significant ischaemic benefit only in this latter group.

61 receptor-1 antagonist vorapaxar, have shown ischaemic benefit.

62 pproach to improve functional recovery after ischaemic brain injury.

63 n of 0.35 or less due to an ischaemic or non-ischaemic cause were randomly assigned (1:1), via an int

64 To review the definition of ischaemic central retinal vein occlusion (CRVO) and stra

65 erved blood-brain barrier integrity after an ischaemic challenge.

66 tive astrocytosis, microinfacrts and diffuse ischaemic changes, all of which can affect both diffusio

67 ed variants were tested in a new independent ischaemic cohort of 1202 WMH patients.

68 are also released by primary afferents under ischaemic conditions.

69 Voxels within ischaemic core had a more severe intracellular acidosis

70 te matter and deep grey matter, resulting in ischaemic damage that ranges from lacunar infarcts to wh

71 he hippocampus is particularly vulnerable to ischaemic damage.

72 failure and reduced ejection fraction due to ischaemic dilated cardiomyopathy resulted in a significa

73 s III or IV symptomatic heart failure due to ischaemic dilated cardiomyopathy, who had left ventricul

74 tcomes in patients with heart failure due to ischaemic dilated cardiomyopathy.

75 f depolarizations act in synergy with direct ischaemic effects of haemorrhage as mechanisms of infarc

76 with positive cardiac biomarkers and either ischaemic electrocardiographic changes or an atheroscler

77 are for moderate and severe neonatal hypoxic-ischaemic encephalopathy (HIE), the leading cause of per

78 rm infants younger than 48 h who had hypoxic ischaemic encephalopathy and electrographic seizures not

79 control in newborn infants who have hypoxic ischaemic encephalopathy and might increase the risk of

80 natal mouse model of cerebral palsy (Hypoxic-Ischaemic Encephalopathy).

81 with aspirin plus a P2Y12 inhibitor prevents ischaemic events after coronary stenting, but increases

82 gnificant difference in serious grade 3 or 4 ischaemic events between groups) was not met (five [3%]

83 tial reversal with anivamersen, would reduce ischaemic events compared with bivalirudin, without incr

84 ials for acute coronary syndromes, to reduce ischaemic events more than clopidogrel, at the expense o

85 ion, there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin.

86 inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increase

87 Main outcomes were mortality, rebleeding, ischaemic events, and mean RBC transfusion.

88 We detected no difference in risk of ischaemic events.

89 estion does ASIC1a activation drive the post-ischaemic forms of AMPAR plasticity in CA1 pyramidal neu

90 e that ASIC1a activation drives certain post-ischaemic forms of CP-AMPAR plasticity.

91 The difference between SN@ and RRP separated ischaemic from non-ischaemic sympathetic nerve fibres.

92 population [95% CI -8.16 to 0.80]; p=0.107), ischaemic heart disease (-2.21 per 100,000 [-6.86 to 2.4

93 st of the time 0.98, 95% CI 0.94-1.01), from ischaemic heart disease (0.97, 0.87-1.10), or from cance

94 ing cause of death in the region in 2013 was ischaemic heart disease (90.3 deaths per 100 000 people)

95 RR 3.78, 2.78-5.14), and ischaemic stroke or ischaemic heart disease (combined RR 2.03, 1.66-2.47).

96 ociated with a significantly reduced risk of ischaemic heart disease (HR 0.80 [95%CI 0.72-0.87]), cer

97 f alanine aminotransferase (ALT) levels with ischaemic heart disease (IHD) and cardiovascular disease

98 246; 95% CI 0.036, 0.469; p = 0.021) and for ischaemic heart disease (n = 6410; excess relative risk/

99 for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to com

100 95-0.928; cardiovascular 0.911, 0.894-0.928; ischaemic heart disease 0.904, 0.882-0.927; cerebrovascu

101 uring follow-up (myocardial infarction [MI], ischaemic heart disease [IHD], cardiomyopathy, and heart

102 een implicated in causing excess deaths from ischaemic heart disease and exacerbations of COPD.

103 in terms of hypertension, diabetes mellitus, ischaemic heart disease and hyperlipidemia.

104 gastrointestinal bleeding, and patients with ischaemic heart disease at baseline.

105 f disability-adjusted life-years (DALYs) was ischaemic heart disease for males and lower respiratory

106 Ischaemic heart disease limits oxygen and metabolic subs

107 Individuals with ischaemic heart disease or COPD were recruited from exis

108 nd older with angiographically proven stable ischaemic heart disease or stage 2 Global initiative for

109 of the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study, were included

110 ients were those aged 18 years or older with ischaemic heart disease undergoing planned stent implant

111 teers, 40 individuals with COPD, and 39 with ischaemic heart disease were recruited.

112 lcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working

113 ty before Jan 1, 2012, from all causes, from ischaemic heart disease, and from cancer in women who di

114 cular disease as the leading cause, five had ischaemic heart disease, and one had lung cancer (Hong K

115 In 2013, the leading cause of YLLs was ischaemic heart disease, and the leading cause of DALYs

116 nary effects of walking in people with COPD, ischaemic heart disease, and those free from chronic car

117 age-adjusted and sex-adjusted mortality for ischaemic heart disease, cancer, and a composite of all

118 stimated the relative risk of mortality from ischaemic heart disease, cerebrovascular disease, chroni

119 leading five causes of DALYs were diabetes, ischaemic heart disease, chronic kidney disease, low bac

120 common non-communicable diseases, including ischaemic heart disease, stroke, chronic obstructive pul

121 ar disease and two (Hong Kong and Macao) had ischaemic heart disease.

122 patho-vagal transmission in hypertension and ischaemic heart disease.

123 neurons, represents a 'neural signature' of ischaemic heart disease.

124 One patient on placebo died of ischaemic heart disease.

125 Chronic angina is a common manifestation of ischaemic heart disease.

126 atment of cardiovascular disease, especially ischaemic heart disease.

127 effects of air pollution in individuals with ischaemic heart disease.

128 are therefore a novel therapeutic target in ischaemic heart disease.

129 ador (Salv) in mouse hearts with established ischaemic heart failure after myocardial infarction indu

130 en delivered at the time of infarct or after ischaemic heart failure following myocardial infarction

131 regenerative therapy in older patients with ischaemic heart failure.

132 All circulatory-disease and ischaemic-heart-disease risk reduces with increasing tim

133 hat occurred in the context of infection and ischaemic hepatitis.

134 was found in samples from human hearts with ischaemic HF.

135 ging and molecular biology in a rat model of ischaemic HF.

136 ssential component of the immune response to ischaemic injury and play an important role in promoting

137 While this intervention limits ischaemic injury, it triggers a new cascade of events th

138 studied by neuroimaging emerge from hypoxic-ischaemic injury, sepsis, metabolic derangements, autoim

139 hat inhibiting RBPJ might be therapeutic for ischaemic injury.

140 D163 in regulating muscle regeneration after ischaemic injury.

141 entricular (LV) viability and function after ischaemic insults in vitro, but its long-term cardioprot

142 ts were categorised as non-ischaemic (NI) or ischaemic (IS) responders.

143 nt early role of CD11b(+) leukocytes in post-ischaemic kidney fibrosis and failure, and suggest a pot

144 ke-related erectile dysfunction and cerebral ischaemic lesion sites using voxel-based lesion mapping.

145 Based on these findings, disseminated ischaemic lesions were diagnosed.

146 ssue regeneration in their ischaemic and non-ischaemic limbs.

147 Immune, infective and ischaemic mechanisms are all potential contributors to t

148 F, 80 placebo), mean age 67.1 (SD 12.9), 92% ischaemic, median NIHSS 10 (IQR 5-15), randomised 11 day

149 d immediately after delayed tPA treatment in ischaemic mice, haemorrhagic transformation was signific

150 C3a-C3a receptor signalling stimulates post-ischaemic neural plasticity and intranasal treatment wit

151 neurons, is also known to contribute to post-ischaemic neuronal death and to physiologically induced

152 well demarcated zones of oedema and hypoxic-ischaemic neuronal injury, consistent with acute infarct

153 Participants were categorised as non-ischaemic (NI) or ischaemic (IS) responders.

154 In the brain, after stroke, a similar post-ischaemic 'no-reflow' has been attributed to capillary c

155 patients with chronic non-arteritic anterior ischaemic optic neuropathy (NAION).

156 scular mortality, myocardial infarction, and ischaemic or haemorrhagic stroke), hospital events for h

157 idence and severity of any recurrent stroke (ischaemic or haemorrhagic; assessed using the modified R

158 ejection fraction of 0.35 or less due to an ischaemic or non-ischaemic cause were randomly assigned

159 ars) admitted to hospital with acute stroke (ischaemic or primary intracerebral haemorrhage) in Engla

160 ly defined as focal neurological symptoms of ischaemic origin resolving spontaneously.

161 rs with grade of collateral circulation, the ischaemic penumbra and clinical functional outcome.

162 The original concept of the ischaemic penumbra suggested imaging of regional cerebra

163 d has been proposed as a metabolic marker of ischaemic penumbra.

164 fat accumulation, and renal function in post-ischaemic Pgc1alpha(-/-) mice.

165 We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve

166 We have examined the role of ASIC1a in AMPAR ischaemic plasticity in organotypic hippocampal slice cu

167 anism with an established model for in vitro ischaemic preconditioning and show that Kv2.1 channel mo

168 We observe that a sublethal ischaemic preconditioning insult also leads to Kv2.1 red

169 mproves cardiac mitochondrial efficiency and ischaemic protection.

170 ve therapeutic potential for protection from ischaemic renal damage.

171 rain barrier (BBB) disruption after cerebral ischaemic/reperfusion (I/R) injury are poorly understood

172 Non-ischaemic responders had a residual predominance of para

173 p=0.005), particularly of disabling or fatal ischaemic stroke (0.64, 0.49-0.84, p=0.0010).

174 jor coronary event (2.44, 95% CI 2.18-2.73), ischaemic stroke (1.68, 95% CI 1.60-1.77), and intracere

175 sease (adjusted HR 2.98 [95% CI 2.76-3.22]), ischaemic stroke (1.72 [1.52-1.95]), stable angina (1.62

176 ecific hazard ratio 2.98, 95% CI 2.76-3.22), ischaemic stroke (1.72, 1.52-1.95), stable angina (1.62,

177 le-blind, phase 2 study, patients with acute ischaemic stroke (aged 18-85 years) from 30 US and Europ

178 Ninety-six children with an arterial ischaemic stroke (AIS) and 43 with a haemorrhagic stroke

179 Arterial ischaemic stroke (AIS) is an important cause of acquired

180 BB) isoform increased in patients with acute ischaemic stroke (AIS).

181 l links between Alzheimer's disease (AD) and Ischaemic Stroke (IS).

182 Patients with acute ischaemic stroke (n = 100) were assessed by brain MRI at

183 and cardiac causes were more associated with ischaemic stroke (p<0.0001).

184 Acute ischaemic stroke accounts for 6.5 million deaths per yea

185 Some further reduction in risk of ischaemic stroke accrued for aspirin only versus control

186 from 32 countries (13 447 cases [10 388 with ischaemic stroke and 3059 intracerebral haemorrhage] and

187 ults (aged 18-85 years) who had a first-ever ischaemic stroke and a motor deficit of the upper extrem

188 ged 18-83 years with moderately severe acute ischaemic stroke and a National Institutes of Health Str

189 f the effect of aspirin on risk of recurrent ischaemic stroke and how this differs by severity at bas

190 n is based on a balance between reduction in ischaemic stroke and increase in major bleeding.

191 acerbate blood-brain barrier breakdown after ischaemic stroke and lead to lethal haemorrhagic transfo

192 ts from 77 hospitals in 17 countries who had ischaemic stroke and occlusion or high-grade stenosis in

193 d one ischaemic stroke) and two PCC related (ischaemic stroke and pulmonary embolism).

194 rimary intracerebral haemorrhage and lacunar ischaemic stroke are acute manifestations of progressive

195 The reduction in risk of recurrent ischaemic stroke at 14 days was most evident in patients

196 Aspirin reduced the 6 week risk of recurrent ischaemic stroke by about 60% (84 of 8452 participants i

197 0.32-0.55, p<0.0001) and disabling or fatal ischaemic stroke by about 70% (36 of 8452 vs 110 of 7326

198 three studies, an extension cohort of 12 577 ischaemic stroke cases and 25 643 controls from NINDS-Si

199 INDS-SiGN, and a validation cohort of 10 307 ischaemic stroke cases and 29 326 controls from METASTRO

200 standard medical care in patients with acute ischaemic stroke caused by occlusion of arteries of the

201 In these trials, patients with acute ischaemic stroke caused by occlusion of the proximal ant

202 my is of benefit to most patients with acute ischaemic stroke caused by occlusion of the proximal ant

203 ety of endovascular treatment (EVT) in acute ischaemic stroke due to cervical and/or cerebral arteria

204 vide timely treatment to patients with acute ischaemic stroke due to large vessel occlusion.

205 evaluation study, adults with supratentorial ischaemic stroke eligible for intravenous thrombolysis w

206 ON THIS ARTICLE: About 20% of patients with ischaemic stroke have a preceding transient ischaemic at

207 tive trials of endovascular thrombectomy for ischaemic stroke have provided level 1 evidence for impr

208 Acute ischaemic stroke in brain areas contributing to male sex

209 higher proportion of patients had recurrent ischaemic stroke in the intra-arterial treatment plus us

210 Ischaemic stroke induces endogenous repair processes tha

211 e use of CMR in the diagnostic evaluation of ischaemic stroke is sparse.

212 Ischaemic stroke is the leading cause of severe long-ter

213 ffect of alteplase on patient survival after ischaemic stroke is the subject of debate.

214 venous alteplase on long-term survival after ischaemic stroke of participants in the Third Internatio

215 on after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% re

216 l benefit of neurothrombectomy within 6 h of ischaemic stroke onset, which has initiated a new era of

217 om disorders of the cerebrovasculature, i.e. ischaemic stroke or haemorrhage.

218 6.15), lung cancer (RR 3.78, 2.78-5.14), and ischaemic stroke or ischaemic heart disease (combined RR

219 ong insulin-resistant patients with a recent ischaemic stroke or TIA, pioglitazone did not affect cog

220 Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) wer

221 ed-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) wit

222 , or death at 90 days in patients with acute ischaemic stroke or transient ischaemic attack when asso

223 s with standard care in anterior circulation ischaemic stroke patients (HERMES Collaboration).

224 In total, 5035 acute ischaemic stroke patients were enrolled.

225 We assessed functional outcome in ischaemic stroke patients with large vessel anterior cir

226 ly reduced soon after stroke onset (84 acute ischaemic stroke patients with or without intravenous tP

227 rrhage and mortality, in patients with acute ischaemic stroke receiving endovascular therapies.

228 Intravenous thrombolysis for ischaemic stroke remains underused worldwide.

229 which have been shown to be associated with ischaemic stroke risk.

230 In analysis of ischaemic stroke subtypes, the myeloperoxidase increasin

231 n with primary intracerebral haemorrhage and ischaemic stroke subtypes.

232 nt-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple

233 ecent advances in the gold standard of acute ischaemic stroke treatment, some aspects of which-aspiri

234 ith poor collaterals, in patients with acute ischaemic stroke under EVT.

235 452 participants in the aspirin group had an ischaemic stroke vs 175 of 7326; hazard ratio [HR] 0.42,

236 TIA or minor stroke had a disabling or fatal ischaemic stroke vs 23 of 5726 in the control group, HR

237 only therapy with proven efficacy for acute ischaemic stroke was alteplase, which is approved for us

238 Alteplase treatment within 6 h after ischaemic stroke was associated with a small, non-signif

239 The effect of aspirin on early recurrent ischaemic stroke was due partly to a substantial reducti

240 In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of ons

241 ed Rankin Scale score 2-4) 6-60 months after ischaemic stroke were implanted with single doses of 2 m

242 years) receiving tPA treatment for confirmed ischaemic stroke were included.

243 Patients with acute ischaemic stroke who could be treated within 8 h of symp

244 ata from 333 consecutive patients with acute ischaemic stroke who underwent susceptibility-weighted i

245 We enrolled 4947 (99%) of 4992 patients with ischaemic stroke who were admitted to hospitals in Tyrol

246 months) rats treated 24 h following cortical ischaemic stroke with human NT3 delivered using a clinic

247 thrombectomy (MT) in patients who had acute ischaemic stroke with large artery occlusive anterior ci

248 d no effect on risk or severity of recurrent ischaemic stroke within 12 weeks (OR 0.90, 95% CI 0.65-1

249 xpansion, one anaphylactic reaction, and one ischaemic stroke) and two PCC related (ischaemic stroke

250 on-fatal myocardial infarction, or non-fatal ischaemic stroke) associated with cumulative burden of r

251 ed to oxygen glucose deprivation (a model of ischaemic stroke), and in hippocampal pyramidal neuron c

252 vs 101 [47%] of 213 patients with recurrent ischaemic stroke), and outnumbered disabling or fatal in

253 the PAR for all stroke worldwide (91.5% for ischaemic stroke, 87.1% for intracerebral haemorrhage),

254 11 stroke survivors with a first-ever TIA or ischaemic stroke, aged 18-50 years.

255 nt of all-cause stroke or systemic embolism, ischaemic stroke, and all-cause mortality.

256 only the first few days after TIA and minor ischaemic stroke, and observational studies show substan

257 In animal models of acute ischaemic stroke, blocking of the leukocyte-endothelium

258 Headache is a common symptom in acute ischaemic stroke, but the underlying mechanisms are inco

259 st cancer, colorectal cancer, endometriosis, ischaemic stroke, leukemia, lymphoma and osteoarthritis.

260 r with a non-cardioembolic, non-severe acute ischaemic stroke, or high-risk transient ischaemic attac

261 nts with a first transient ischaemic attack, ischaemic stroke, or myocardial infarction treated with

262 domised trials of endovascular treatment for ischaemic stroke, published in 2013, were neutral but li

263 Patients can present with headache, ischaemic stroke, subarachnoid haemorrhage, or symptoms

264 control in secondary prevention after TIA or ischaemic stroke, we studied the effects of aspirin on t

265 ted with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, diabetes, apo

266 the major venous imaging-based biomarkers in ischaemic stroke.

267 tly correlates with stroke outcomes in acute ischaemic stroke.

268 l patterns associated with headache in acute ischaemic stroke.

269 ated to the development of headache in acute ischaemic stroke.

270 on motor recovery in patients after an acute ischaemic stroke.

271 or untreated control) in patients with acute ischaemic stroke.

272 rd care or standard care alone within 6 h of ischaemic stroke.

273 outcome when delivered within 4.5 h of acute ischaemic stroke.

274 f pH-weighted imaging in patients with acute ischaemic stroke.

275 ppocampal CA1 region is highly vulnerable to ischaemic stroke.

276 on of tissue plasminogen activator (tPA) for ischaemic stroke.

277 he only approved medical treatment for acute ischaemic stroke.

278 prospective cohort of 12 patients with acute ischaemic stroke.

279 fe and well tolerated in patients with acute ischaemic stroke.

280 icity in the subacute to chronic phase after ischaemic stroke.

281 hted imaging (DWI) typically indicates acute ischaemic stroke.

282 n the diagnostic evaluation of patients with ischaemic stroke.

283 acy and safety of thrombolytic treatment for ischaemic stroke.

284 ting the best therapy in patients with acute ischaemic stroke.

285 cule alpha4 integrin, in patients with acute ischaemic stroke.

286 'cryptogenic' stroke accounts for 30-40% of ischaemic strokes despite extensive diagnostic evaluatio

287 Of the 597 disabling/fatal incident ischaemic strokes, 369 occurred at age >/=80 years, of w

288 rial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fi

289 ean age 60.5 +/- 10.5 years) with first-ever ischaemic strokes, we assessed erectile function after a

290 een SN@ and RRP separated ischaemic from non-ischaemic sympathetic nerve fibres.

291 ORBITA enrolled 230 patients with ischaemic symptoms.

292 sulted in haemorrhagic transformation in the ischaemic territory 1 day after ischaemia.

293 The Pragmatic Ischaemic Thrombectomy Evaluation (PISTE) trial was a mu

294 eactive protein (mCRP) appears in the ECM of ischaemic tissue after stroke, associating with microvas

295 s within the first 7 days after stroke, post-ischaemic tPA treatment led to sustained suppression of

296 VMs, stroke (separately for haemorrhagic and ischaemic), transient ischaemic attack (TIA) and subarac

297 the diagnosis of the BD type of subcortical ischaemic vascular disease.

298 antiplatelet treatment is recommended after ischaemic vascular events, on the basis of trials done m

299 Proton MR spectroscopic imaging showed ischaemic white matter and permeability of the blood-bra

300 he survival of brain cancer cells within the ischaemic zones of gliomas.